Q-omics provides the consensus-scored TBC1D13 profile across patient tissues and cancer cell-line models. TBC1D13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TBC1D13 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TBC1D13 protein abundance shows 19,824 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where TBC1D13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D13 survival associations across molecular data types. TBC1D13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D13 RNA expression–survival associations across cancer types. High TBC1D13 expression shows unfavorable associations in ACC, LIHC, SKCM and MESO, but favorable associations in KIRC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TBC1D13 RNA expression.
This table summarizes TBC1D13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D13 shows lower tumor expression in KIRC, KICH, KIRP and THCA and higher tumor expression in HNSC and LIHC. The KIRC box plot shows higher TBC1D13 RNA expression in normal versus tumor tissue (log2 FC = −0.948, t-test p < 0.001).
This table shows molecular features associated with TBC1D13 in patient tissues and cancer cell lines. In patient samples, TBC1D13 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
